^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    OX40 ligand inhibitor

    Related drugs:
    5d
    Machine learning models predict the immunotherapy response in tumors on the basis of DNA methylation. (PubMed, Epigenomics)
    Differentially methylated sites enriched the ubiquitin-proteasome pathway, with most loci located in the N shore region of CpG islands...Tumor methylation sites hold promise as predictive biomarkers for immunotherapy efficacy. The SVM model is the optimal machine learning approach for predicting methylation sites in immunotherapy.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    22d
    RIVER-ASTHMA: Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study (clinicaltrials.gov)
    P2, N=335, Active, not recruiting, Sanofi | Trial completion date: Jun 2029 --> Sep 2026 | Trial primary completion date: Jun 2029 --> Sep 2026
    Trial completion date • Trial primary completion date
    29d
    SAPIOX: A FIRST-IN-HUMAN PHASE I TRIAL OF OX118 IN HEALTHY VOLUNTEERS (2024-515378-28-00)
    P1, N=32, Completed, Oxion Biologics AB | Recruiting --> Completed
    Trial completion • First-in-human
    1m
    AQUA: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (clinicaltrials.gov)
    P3, N=636, Recruiting, Sanofi | N=390 --> 636 | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: May 2026 --> Sep 2027
    Enrollment change • Trial completion date • Trial primary completion date
    1m
    Targeting Human Epidermal Growth Factor Receptor 2 in Bladder Cancer: Evaluating Its Role as a More Robust Clinicopathological Biomarker Compared to Programmed Death Ligand 1 Expression. (PubMed, Urol Res Pract)
    The HER2/neu was an independent clinicopathological biomarker associated with nodal involvement and aggressive tumor biology in urothelial carcinoma. PD-L1 showed limited clinicopathological utility in this cohort, though it retains predictive value for immune checkpoint inhibitor therapy.   Cite this article as: Mittal A, Malhotra K, Panwar V, Kishore S, Taher M, Singhal A. Targeting human epidermal growth factor receptor 2 in bladder cancer: evaluating its role as a more robust clinicopathological biomarker compared to programmed death ligand 1 expression. Urol Res Pract. 2026, 52, 0061, doi: 10.5152/tud.2026.25061.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • NODAL (Nodal Growth Differentiation Factor)
    |
    PD-L1 expression • HER-2 overexpression • PD-L1 expression + HER-2 overexpression
    1m
    A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of subcutaneous NAV-242 in Healthy Adults. (ACTRN12626000155392)
    P1, N=48, Recruiting, Navigator Medicines | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    1m
    Mainsail: A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=150, Recruiting, Navigator Medicines, Inc.
    Trial initiation date
    2ms
    ATLANTIS: Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=999, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=212, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion
    2ms
    Local Promoter Methylation Disorder algorithm reveals bidirectional epigenetic disruption in DNMT3A-mutated AML and predicts azacitidine treatment response. (PubMed, Front Oncol)
    The LPMD algorithm effectively captured DNMT3A mutation-associated epigenetic instability (Cohen's d = 0.8, p < 0.001), with the strongest effects observed in the 5'UTR-Exon1 region (d = 0.74) and a gradient pattern from CpG islands to shores (d: 0.59→0.54→0.43). The 5-DMDR panel offers a practical tool for azacitidine response prediction, while dynamic LPMD monitoring provides a potential biomarker for therapeutic guidance. These findings establish methylation disorder as a clinically actionable dimension of epigenetic dysregulation in myeloid malignancies.
    Journal
    |
    DNMT3A (DNA methyltransferase 1)
    |
    azacitidine
    2ms
    Mainsail: A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=115, Recruiting, Navigator Medicines, Inc.
    New P2 trial
    3ms
    CHROMA CD: A study to investigate efficacy and safety of brivekimig in participants with Crohns disease (clinicaltrials.gov)
    P2, N=99, Recruiting, Sanofi
    Trial initiation date